With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...

The pursuit of accurate temperature characterisation in GaN HEMTs confronts fundamental limitations of existing methodologies ...

Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved ...

1 Christoffersen M et al. Transthyretin Tetramer Destabilization and Increased Mortality in the General Population. JAMA ...

BridgeBio Pharma’s Beyonttra to treat transthyretin-mediated amyloid cardiomyopathy receives Japanese approval: Palo Alto, California Monday, March 31, 2025, 17:00 Hrs [IST] Bri ...

The test also assesses four alleles known to increase heart disease risk and determines ... about half of whom have a pathogenic variant in one of three genes linked to cardiovascular disease: 16 ...

For example, if you take a pregnancy test too early, you could get a false-negative result because your body isn’t producing enough human chorionic gonadotrophin (HCG) yet. To ensure you get the most ...

Drugs that have successfully completed late-stage studies include inotersen, an antisense drug the company is developing to treat TTR amyloidosis. Volanesorsen, an antisense drug discovered by ...

“The results from the NEURO-TTR study support a favourable benefit-risk profile for inotersen in patients with hATTR. We believe inotersen has the potential to give people living with this ...

Explore Q1 2025's biotech stock moves, from CervoMed's 300% surge to Septerna's struggles. Click for my review of the quarter ...